DALLAS, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that, on January 2, 2024, Taysha's Board of Directors granted Meredith Schultz, M.D., M.S., an option to purchase 257,700 shares of the Company's common stock in connection with her employment as Taysha’s new Senior Vice President, Clinical Development and Medical Affairs. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to Ms. Schultz entering into employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option has an exercise price of $1.71 per share, which is equal to the closing price of Taysha's common stock on the date of grant. The stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of the stock option is subject to such employee's continued service to Taysha on each vesting date.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program. Together, we leverage our fully integrated platform with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

Company Contact:
Hayleigh Collins
Director, Head of Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Carolyn Hawley
Canale Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.